Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why is the government so scared of directly negotiating drug prices?

Robert Laszewski
Meds
August 29, 2020
Share
Tweet
Share

President Trump recently signed two executive orders directly related to prescription drug prices in the U.S.

One order would allow the “reimportation” of prescription drugs from Canada. This longstanding idea would allow U.S. pharmacies and drug wholesalers the ability to pay generally much lower prices for their prescription drugs by getting them from Canadian suppliers who benefit from government management of the system. Many consumers have been buying direct from Canadian pharmacies for years since current prohibitions have not been enforced against individuals.

The second order would direct Medicare to pay no more for prescription drugs than a basket of industrialized countries pay for the same drugs.

Both orders would take advantage of the fact that these nations directly negotiate the price their government-run health systems pay the drug companies.

Republicans have long opposed, and Democrats have long supported, the U.S. federal government directly negotiating drug prices with Big Pharma for programs like Medicare and Medicaid.

Democrats generally point to the success in lowering costs that these nations have had in direct negotiation. Republicans have generally called this government price controls and worry that it would be one more step on a journey to single-payer government management of the system.

The challenge both sides see is in controlling the prices of drugs on the one hand but continuing to encourage the incredible innovation the pharmaceutical and biotech industry has historically delivered to the American patient.

What everyone can agree on is that it is only the U.S. that pays these high drug prices, and therefore pays for the bulk of the innovation, while the rest of the world “free loads” on the backs of American consumers, taxpayers, and employers who pay the health insurance bill.

The Trump administration has been talking about these ideas for years. Why sign these executive orders now?

While Trump has consistently underestimated the threat posed by the COVID-19 pandemic, cases and deaths have risen to troubling levels. The voter segment most threatened by the impact of the disease are seniors.

As a result, Trump is in trouble with that group. According to the July 17th Wall Street Journal/NBC News poll, Trump beat Hillary Clinton by seven points among seniors in 2016 but is now trailing Biden by one point––an eight-point swing.

Announcing a plan to let seniors cut their drug costs can only help him.

But why this plan?

ADVERTISEMENT

He doesn’t favor government-run health care solutions, but he does favor letting Americans access the drug prices achieved by single-payer government-run health systems the likes of Canada, Great Britain, France, and Germany?

I have never understood the Republican objection to the federal government negotiating drug prices with the pharmaceutical industry.

Why is the drug industry any different than any other technology industry the government buys from?

When it comes to world-class innovation, where is technology more important than in aerospace, for example?

Can you imagine our having bought the F-35 fighter without competitive bidding? Can you imagine NASA buying rockets and space capsules without competitive bidding? Yet, our aerospace technology has led the world for decades. The old astronaut joke in the 60s was about being sent up on top of a rocket built by the lowest bidder! And, they got to the moon in ten short years.

But, the drug industry is too good and too important to be subject to putting their drugs side by side with their competitors in a competition for who provides the most value for the price?

Many of these “socialist” countries utilize various forms of a drug bid process called “reference-based pricing.” Simply, drugs in the same class are put on a bid list, and the government health plan will pay for any of the drugs on the list up to the price of the best outcomes adjusted bid––who’s got the best drug for the money. If the consumer wants a different drug, they can pay the difference.

That isn’t socialism––it’s the best of free market economics.

But Trump just can’t bring himself to propose such a plan. He has to try to get the same result by piggybacking on the likes of the French and the Brits and their government-run systems by accessing their value-based competitive bidding through the back door.

At least he is better than most Congressional Republicans who every time they hear about putting drugs out to bid scream, “Socialism!”

With anything other than the Big Pharma, a “no-bid” acquisition would lead to a Republican Congressional investigation.

Robert Laszewski is president, Health Policy and Strategy Associates and blogs at Health Care Policy and Marketplace Review.

Image credit: Shutterstock.com

Prev

What it’s like to work in long-term care during the pandemic

August 29, 2020 Kevin 0
…
Next

How to help families struggling to find their way in a foreign culture [PODCAST]

August 29, 2020 Kevin 0
…

Tagged as: Medications, Public Health & Policy

Post navigation

< Previous Post
What it’s like to work in long-term care during the pandemic
Next Post >
How to help families struggling to find their way in a foreign culture [PODCAST]

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Robert Laszewski

  • Inside the $1.9 trillion coronavirus stimulus bill is a political time bomb for Republicans

    Robert Laszewski
  • What does Kelly Loeffler’s health plan do to coverage for preexisting conditions?

    Robert Laszewski
  • Joe Biden won. What does that mean for health care?

    Robert Laszewski

Related Posts

  • Negotiating lower drug prices in America: The tradeoffs are worth it.

    Konye Ori
  • Beyond the EpiPen: Irrational drug prices are now pervasive

    Stephen C. Schimpff, MD
  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • How hospitals can impact generic drug companies

    Mark Kelley, MD
  • Drug ads are a campaign against physician trust

    Judy Salz, MD
  • Crippling drug costs: the role of insurers

    Janice Boughton, MD

More in Meds

  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Functional precision oncology: a game changer in cancer therapy

    Chris Apfel, MD, PhD, MBA
  • Most Popular

  • Past Week

    • How dismantling DEI endangers the future of medical care

      Shashank Madhu and Christian Tallo | Education
    • How scales of justice saved a doctor-patient relationship

      Neil Baum, MD | Physician
    • “Think twice, heal once”: Why medical decision-making needs a second opinion from your slower brain (and AI)

      Harvey Castro, MD, MBA | Tech
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Do Jewish students face rising bias in holistic admissions?

      Anonymous | Education
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • Why true listening is crucial for future health care professionals [PODCAST]

      The Podcast by KevinMD | Podcast
    • Love on life support: a powerful reminder from the ICU

      Syed Ahmad Moosa, MD | Physician
    • Surviving kidney disease and reforming patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why we fear being forgotten more than death itself

      Patrick Hudson, MD | Physician
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Antimicrobial resistance: a public health crisis that needs your voice [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 6 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • How dismantling DEI endangers the future of medical care

      Shashank Madhu and Christian Tallo | Education
    • How scales of justice saved a doctor-patient relationship

      Neil Baum, MD | Physician
    • “Think twice, heal once”: Why medical decision-making needs a second opinion from your slower brain (and AI)

      Harvey Castro, MD, MBA | Tech
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Do Jewish students face rising bias in holistic admissions?

      Anonymous | Education
    • Why shared decision-making in medicine often fails

      M. Bennet Broner, PhD | Conditions
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • Why true listening is crucial for future health care professionals [PODCAST]

      The Podcast by KevinMD | Podcast
    • Love on life support: a powerful reminder from the ICU

      Syed Ahmad Moosa, MD | Physician
    • Surviving kidney disease and reforming patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why we fear being forgotten more than death itself

      Patrick Hudson, MD | Physician
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Antimicrobial resistance: a public health crisis that needs your voice [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why is the government so scared of directly negotiating drug prices?
6 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...